" I would think after seeing the results, any scientist or physician who understands clinical trials would come to the same conclusion, not the opposite conclusion. " These days, the F. D. A. has shown a willingness to approve products that have shown promise based on intermediate measures, like a shrinking tumor, rather than   outcomes like survival rates   